Aviva PLC Buys 48 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Aviva PLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,833 shares of the company’s stock after acquiring an additional 48 shares during the period. Aviva PLC’s holdings in Medpace were worth $609,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in MEDP. Pallas Capital Advisors LLC increased its position in shares of Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after purchasing an additional 2,101 shares during the period. Barclays PLC grew its stake in shares of Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after purchasing an additional 8,275 shares during the period. Sanctuary Advisors LLC raised its holdings in shares of Medpace by 20.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after buying an additional 844 shares in the last quarter. SYM FINANCIAL Corp acquired a new position in shares of Medpace in the 4th quarter worth approximately $320,000. Finally, Tokio Marine Asset Management Co. Ltd. bought a new position in shares of Medpace during the 4th quarter worth approximately $9,335,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

MEDP stock opened at $282.33 on Friday. The stock has a market capitalization of $8.53 billion, a PE ratio of 22.35, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. The company has a 50 day moving average price of $324.57 and a 200 day moving average price of $334.57. Medpace Holdings, Inc. has a fifty-two week low of $272.00 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MEDP has been the topic of a number of analyst reports. Robert W. Baird upped their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Leerink Partners started coverage on shares of Medpace in a report on Monday, March 24th. They issued a “market perform” rating and a $330.00 target price on the stock. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Mizuho decreased their price objective on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Truist Financial cut their target price on shares of Medpace from $347.00 to $333.00 and set a “hold” rating for the company in a research note on Thursday. Nine equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $361.90.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.